Results From the CELESTIAL Trial for Patients with Advanced HCC
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses results of the CELESTIAL trial. The results were clinically and statistically significant, Abou-Alfa notes.
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses results of the CELESTIAL trial. The results were clinically and statistically significant, Abou-Alfa notes.
This randomized phase III trial compared treatment with cabozantinib (Cabometyx) versus a placebo in patients with advanced hepatocellular carcinoma (HCC) who had received a prior sorafenib (Nexavar) treatment. Findings showed a median overall survival (OS) of 10.2 months in the cabozantinib arm versus 8 months in the placebo arm.
There was also a progression-free survival rate over 5 months versus 1.5 months and a response rate of 4% versus 0.4% in the cabozantinib versus placebo arms, respectively. Patients experienced grade 3 and 4 adverse events, but none were unexpected for this drug, says Abou-Alfa.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
